Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL

Post Kala Azar Dermal Leishmaniasis Clinical Trial

Official title:

Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00982774
• Other study ID #: IDRI-LVPTC-107
• Status: Completed
• Phase: Phase 1
• First received: September 21, 2009
• Last updated: June 23, 2011
• Start date: April 2009
• Est. completion date: April 2011

Study information

• Verified date: June 2011
• Source: IDRI
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 7 Years to 40 Years

Eligibility

Inclusion Criteria:

• Males and females = 7 years and < 40 years of age.

• Must have a skin rash of > 6 months duration compatible with a diagnosis of PKDL following a history of successful treatment of VL, and histopathology consistent with PKDL (Section 6.1).

• Female patients of child bearing age must have a negative serum pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 59 of the study. These precautions are necessary due to unknown effects that LEISH-F2 + MPL-SE might have in a fetus or newborn infant.

• The following laboratory blood tests must have values within the normal ranges at screening (Appendix 3): sodium, potassium, urea, total bilirubin, glucose, creatinine, hemoglobin and platelet count. ALT, AST, alkaline phosphatase, and total WBC count values (commonly elevated in PKDL patients) must be below grade 2 at screening (Appendix 3).

• The following serology tests must be negative at screening: HIV 1/2 (in patients >14 years of age), hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All patients (or their parents) will receive HIV-related counseling prior to testing. Patients with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.

• Normal ECG.

• Potential study patients (or their guardians) must give written informed consent, be willing to be admitted to hospital for a minimum of 40 days and up to 60 days, able to attend all required follow-up visits, have a permanent address, and be reachable by study site personnel.

Exclusion Criteria:

• Presence of other skin conditions.

• Anti-leishmanial treatment within the past 30 days.

• History of previous exposure to Leishmania vaccines.

• Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.

• Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.

• History of autoimmune disease or other causes of immunosuppressive states.

• History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Patients presenting with concomitant illness will be referred for standard clinical care).

• History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.

• History of significant psychiatric illness.

• Known to be a current drug or alcohol abuser.

• Patients with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.

• Patients who are unlikely to cooperate with the requirements of the study protocol.

• Known allergy or contraindication to SSG.

• Regardless of eligibility, standard clinical care will be provided (at no cost to the patient) to all PKDL patients screened for participation in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leishmaniasis
• Leishmaniasis, Visceral
• Post Kala Azar Dermal Leishmaniasis

Intervention

Biological:
• LEISH-F2 + MPL-SE vaccine
LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart

Locations

Country	Name	City	State
Sudan	IEND	Khartoum

Sponsors (1)

Lead Sponsor	Collaborator
IDRI

Country where clinical trial is conducted

Sudan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the safety of the vaccine given as 3 sc injections every 14 days in combination with standard SSG therapy in patients with persistent PKDL.		one year	Yes
Secondary	Assess the effect of the vaccine on the clinical course of PKDL.		one year	No
Secondary	To evaluate the immunogenicity of the vaccine by evaluating antibody and T-cell responses to the LEISH-F2 protein and Soluble Leishmania Antigen (SLA).		one year	No